Novel Markers of Atherosclerosis Risk
In this presentation, Sotirios “Sam” Tsimikas, MD, Professor of Medicine and Director of Vascular Medicine at the University of California, San Diego, discusses new and emerging biomarkers in atherosclerosis risk that may have significant clinical impact in the future treatment and management of cardiovascular disease.
Tools for Your Patients
A Patient-Centric Cardiovascular Disease Management Program
Our Berkeley HeartLab 4myheart Program empowers patients to make changes that may improve clinical outcomes and quality of life.
The 4myheart program provides ongoing interaction with each patient through individual education and group sessions. Berkeley HeartLab Clinical Educators help patients understand lab results, their treatment plan and lifestyle goals. Subsequent tests are used to assess the patient’s progress.
Do your patients have the genetic variation that is associated with clopidogrel resistance? Find out with the AccuType® CP test.
Dr. Jay Wohlgemuth, VP Science and Innovation
Dr. Jay Wohlgemuth, MD, who specializes in cardiovascular medicine, shares insights on pharmacogenic tools in cardiovascular disease management.
View and securely share patient history: lab results, prescriptions and with our certified Care360® EHR, the entire patient chart. Enjoy mobile access and ePrescribe from many devices including the iPhone® and iPad®.